Core Viewpoint - The company has approved the conclusion of a fundraising project and plans to permanently supplement its working capital with the remaining funds, amounting to approximately 55.68 million yuan [1]. Group 1 - The company held its third board meeting and the fourth audit committee meeting on December 18, 2025 [1]. - The board approved the conclusion of the "substrate-level testing probe R&D mass production project" under the fundraising project initiated in 2021 [1]. - The estimated surplus amount from the fundraising project is 55.68 million yuan [1].

Core Viewpoint - The company has announced the completion of a fundraising project and plans to permanently allocate the surplus funds to working capital for daily operations [1] Group 1: Project Completion - The company held its third board meeting on December 18, 2025, to review and approve the completion of the "substrate-level testing probe R&D mass production project" [1] - The project has been completed and has reached the intended usable state as of December 15, 2025 [1] Group 2: Financial Details - The surplus funds from the completed project amount to 55.6827 million yuan [1] - The company intends to use the surplus funds to supplement its working capital permanently [1] - The actual amount will be based on the balance of the fundraising account on the day of the fund transfer [1]

Core Viewpoint - The company announced the completion of its substrate-level testing probe R&D project and plans to permanently allocate the surplus funds of 55.6827 million yuan to supplement its working capital [1] Group 1: Project Financials - The initial plan was to use 125 million yuan of raised funds for the project, but the actual investment amounted to 69.4513 million yuan [1] - The project generated interest and cash management income, net of fees, totaling 8.1178 million yuan [1] - There remains a payment obligation of 7.6238 million yuan related to the project [1] Group 2: Cost Management - The company achieved a surplus by strictly controlling costs and improving the efficiency of fund utilization [1] - The surplus funds will be used to support daily production and operational activities [1]

证券代码：688661 证券简称：和林微纳 编号：2025-043 苏州和林微纳科技股份有限公司 关于 2021 年度向特定对象发行股票部分募投项目延 期并重新论证可行性的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州和林微纳科技股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日 召开的第三届董事会第二次会议审议通过了《关于 2021 年度向特定对象发行股 票部分募投项目延期并重新论证可行性的议案》。结合目前公司 2021 年度向特 定对象发行股票募投项目的实际进展情况，董事会同意公司在保持募投项目的实 施主体、投资总额和资金用途等均不发生变化的情况下，根据募投项目当前的实 际建设进度，将公司 2021 年度向特定对象发行股票募投项目未结项部分"MEMS 工艺晶圆测试探针研发量产项目"及"基板级测试探针研发量产项目"的预定可 使用状态日期分别延长至 2027 年 9 月和 2025 年 12 月。本议案不涉及募集资金 用途变更，无需提交股东大会审议。现将相关情况公告如下： 一、募集资金基本情况 根 ...